Activation of the FGF2/FGFR1 Autocrine Loop for Cell Proliferation and Survival in Uveal Melanoma Cells

被引:44
作者
Lefevre, Gaelle [1 ,2 ,3 ]
Babchia, Narjes [1 ,2 ,3 ]
Calipel, Armelle [1 ,2 ,3 ,4 ]
Mouriaux, Frederic [4 ]
Faussat, Anne-Marie [1 ]
Mrzyk, Stefanie [5 ]
Mascarelli, Frederic [1 ,2 ,3 ]
机构
[1] Univ Paris 06, Cordeliers Res Ctr, Paris, France
[2] Paris Descartes Univ, Paris, France
[3] INSERM, U872, F-75006 Paris, France
[4] CHU Caen, Serv Ophtalmol, F-14000 Caen, France
[5] Univ Eye Hosp Essen, Essen, Germany
关键词
FIBROBLAST-GROWTH-FACTOR; FACTOR-I RECEPTOR; BRAF MUTATIONS; MALIGNANT MELANOMAS; REGULATED KINASE; IMATINIB MESYLATE; HUMAN MELANOCYTES; P53; PATHWAYS; B-RAF; EXPRESSION;
D O I
10.1167/iovs.08-2378
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. Constitutive activation of ERK1/2 controls proliferation of uveal melanoma cells. Because an autocrine fibroblast growth factor (FGF) activation loop controls ERK1/2 activation in many cancers, this study was conducted to examine the role of the FGF/FGF receptor autocrine loop in the ERK1/2dependent proliferation and survival of uveal melanoma cells. METHODS. Primary tumors and cell lines (OCM1, MKT-BR, SP6.5, Mel270 and 92.1) were used to define the role of the FGF/ FGFR system in human uveal melanoma. Cell proliferation was assessed by MTT-staining, and apoptosis was quantified by flow cytometry. Specific pharmacologic inhibitors of ERK1/2 and FGFR1, an anti-FGF2 neutralizing antibody and an antisense oligonucleotide directed against FGF2 were used to analyze signaling in the FGF/ FGFR autocrine loop. RESULTS. FGF1, FGF2, and their FGFR1 receptor were strongly expressed in the primary uveal melanomas. All five uveal melanoma cell lines expressed and secreted FGF2. They also expressed FGFR1. Cell proliferation was strongly reduced by the antisense oligonucleotide-mediated depletion of endogenous FGF2, immunoneutralization of secreted FGF2, and pharmacologic inhibition of FGFR1. The FGF2/FGFR1-mediated signaling pathway was identified by showing that inhibition of either FGF2 or FGFR1 reduced ERK1/2 activation, cell proliferation, and survival. CONCLUSIONS. The FGF/FGFR/ERK signaling pathway may be a target for therapeutic strategies against uveal melanoma. (Invest Ophthalmol Vis Sci. 2009; 50: 1047-1057) DOI: 10.1167/iovs.082378
引用
收藏
页码:1047 / 1057
页数:11
相关论文
共 75 条
  • [11] Deregulation of the Rb and p53 pathways in uveal melanoma
    Brantley, MA
    Harbour, JW
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (06) : 1795 - 1801
  • [12] Both FGF1 and Bcl-x synthesis are necessary for the reduction of apoptosis in retinal pigmented epithelial cells by FGF2: role of the extracellular signal-regulated kinase 2
    Bryckaert, M
    Guillonneau, X
    Hecquet, C
    Courtois, Y
    Mascarelli, F
    [J]. ONCOGENE, 1999, 18 (52) : 7584 - 7593
  • [13] Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells
    Calipel, A
    Mouriaux, F
    Glotin, AL
    Malecaze, F
    Faussat, AM
    Mascarelli, F
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (14) : 9238 - 9250
  • [14] Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway
    Calipel, A
    Lefevre, G
    Pouponnot, C
    Mouriaux, F
    Eychène, A
    Mascarelli, F
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) : 42409 - 42418
  • [15] Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO
  • [16] 2-8
  • [17] Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF
    Christensen, C
    Guldberg, P
    [J]. ONCOGENE, 2005, 24 (41) : 6292 - 6302
  • [18] Lack of BRAF mutation in primary uveal melanoma
    Cohen, Y
    Goldenberg-Cohen, N
    Parrella, P
    Chowers, I
    Merbs, SL
    Pe'er, J
    Sidransky, D
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (07) : 2876 - 2878
  • [19] Normal human melanocytes that express a bFGF transgene still require exogenous bFGF for growth in vitro
    Coleman, AB
    Lugo, TG
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (05) : 793 - 799
  • [20] Cruz F, 2003, CANCER RES, V63, P5761